Somatically acquired mutations in primary myelofibrosis : A case report and meta-analysis
Copyright © 2020, Spandidos Publications..
Familial myeloproliferative disease (MPD) cases account for 7.6% of the global MPD cases. The present study reported 2 cases of primary myelofibrosis (PMF). The patients were two sisters; the older sister succumbed to the disease at the age of 37, whereas the younger sister maintained a stable disease status and gave birth to a son through in vitro fertilization. Genetic analysis of bone marrow DNA samples showed that both sisters carried a Janus kinase 2 (JAK2) V617F mutation, and the older sister also had a trisomy 8 chromosomal abnormality (47, XX, +8). A systematic literature search was also performed using PubMed, CNKI and Wanfang databases, to determine the association between JAK2 and PMF. Following comprehensive screening of the published literature, 19 studies were found to be eligible for the current meta-analysis. The results showed that JAK2 V617F was a risk factor of PMF, and no sex dimorphism was observed in JAK2 V617F mutation prevalence amongst all PMF cases. In addition, there was a lack of association between the JAK2 V617F mutation and PMF-related mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Experimental and therapeutic medicine - 21(2021), 3 vom: 05. März, Seite 193 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xia, Yongming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Familial |
|---|
| Anmerkungen: |
Date Revised 26.01.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3892/etm.2021.9625 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320509052 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320509052 | ||
| 003 | DE-627 | ||
| 005 | 20231225173733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/etm.2021.9625 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320509052 | ||
| 035 | |a (NLM)33488802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xia, Yongming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Somatically acquired mutations in primary myelofibrosis |b A case report and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020, Spandidos Publications. | ||
| 520 | |a Familial myeloproliferative disease (MPD) cases account for 7.6% of the global MPD cases. The present study reported 2 cases of primary myelofibrosis (PMF). The patients were two sisters; the older sister succumbed to the disease at the age of 37, whereas the younger sister maintained a stable disease status and gave birth to a son through in vitro fertilization. Genetic analysis of bone marrow DNA samples showed that both sisters carried a Janus kinase 2 (JAK2) V617F mutation, and the older sister also had a trisomy 8 chromosomal abnormality (47, XX, +8). A systematic literature search was also performed using PubMed, CNKI and Wanfang databases, to determine the association between JAK2 and PMF. Following comprehensive screening of the published literature, 19 studies were found to be eligible for the current meta-analysis. The results showed that JAK2 V617F was a risk factor of PMF, and no sex dimorphism was observed in JAK2 V617F mutation prevalence amongst all PMF cases. In addition, there was a lack of association between the JAK2 V617F mutation and PMF-related mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Janus kinase 2 V617F | |
| 650 | 4 | |a familial | |
| 650 | 4 | |a primary myelofibrosis | |
| 650 | 4 | |a somatic mutation | |
| 700 | 1 | |a Hong, Qingxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Zhibin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shijun |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Shiwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental and therapeutic medicine |d 2010 |g 21(2021), 3 vom: 05. März, Seite 193 |w (DE-627)NLM206343205 |x 1792-1015 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:3 |g day:05 |g month:03 |g pages:193 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/etm.2021.9625 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 3 |b 05 |c 03 |h 193 | ||